 Biomerica Inc. NASDAQ: BMRA today announced it has signed two separate definitive license agreements with Mount Sinais Icahn School of Medicine in New York to license technologies pertaining to a laboratory version serological test for SARS-CoV-2 COVID-19 virus infection which have been developed at Mount Sinai. This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States. Biomerica has extensive serological test development, scale-up and manufacturing capabilities and expertise. 